SCHEMBL4666703

SCHEMBL4666703

CC(C)CC1OC(=O)C(C(=O)C2CCCO2)=C1O

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.37
GAA P10253 1/20 0.37
PTPN1 P18031 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 2/20 0.35
ACP1 P24666 2/20 0.35
CDC25B P30305 2/20 0.35
RECQL P46063 1/20 0.35
PTPN2 P17706 1/20 0.35
DUSP3 P51452 1/20 0.35
HPSE Q9Y251 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
ALDH1A1 P00352 5/20 0.33
HTT P42858 2/20 0.33
HSD17B10 Q99714 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664985 0.89 HPGD (0.35) HPGDGAAPTPN1TDP1MAPT
SCHEMBL4664922 0.80 PTPN1 (0.35) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4664905 0.75 PTPN1 (0.39) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4662939 0.75 PTPN1 (0.37) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4663314 0.75 PTPN1 (0.44) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4663317 0.75 PTPN1 (0.44) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4664793 0.73 GLA (0.34) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4666707 0.73 PKM (0.39) GAAMAPTALDH1A1KDM4ETSHR
SCHEMBL4664706 0.72 PTPN1 (0.49) PTPN1TDP1MAPTACP1CDC25B
SCHEMBL4663076 0.72 PTPN1 (0.36) PTPN1TDP1MAPTACP1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US claimed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 EP claimed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US claimed
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US disclosed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 EP disclosed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS BACE1, PSEN1, BACE2 HPGD 4570/4885GAA 70/4885PTPN1 2489/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 HPGD 4570/4885GAA 70/4885PTPN1 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.